CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.
When CDK12/13 stalls, healthy prostate cells take a malignant turn
- Post author:
- Post published:October 7, 2024
- Post category:uncategorized